Cargando…
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
Glioblastomas (GBMs) are aggressive brain tumours with a dismal prognosis, despite combined surgery, radio- and chemotherapy. Close to 90 % of all GBMs harbour a deregulated PI3K pathway, which is essential in regulating central cellular functions such as proliferation, cell growth, motility and sur...
Autores principales: | Netland, I. A., Førde, H. E., Sleire, L., Leiss, L., Rahman, M. A., Skeie, B. S., Miletic, H., Enger, P. Ø., Goplen, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972854/ https://www.ncbi.nlm.nih.gov/pubmed/27283525 http://dx.doi.org/10.1007/s11060-016-2158-1 |
Ejemplares similares
-
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016) -
Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth
por: Padthaisong, Sureerat, et al.
Publicado: (2018) -
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016) -
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015) -
NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction
por: Yang, Shida, et al.
Publicado: (2017)